Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Laboratorios Farmaceuticos Rovi's Enterprise Value for the quarter that ended in Jun. 2026 was €3,008.4 Mil.
Laboratorios Farmaceuticos Rovi's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €239.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi EV-to-EBIT Related Terms
Laboratorios Farmaceuticos Rovi EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's EV-to-EBIT falls into.
Laboratorios Farmaceuticos Rovi's current Enterprise Value is €2,970.0 Mil.
Laboratorios Farmaceuticos Rovi's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €239.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (FRA:41L) has a EV-to-EBIT of 12.42 as of Aug. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 46% below median its historical median of 23.18. Over the past decade, Laboratorios Farmaceuticos Rovi's EV-to-EBIT has ranged from 7.10 to 102.09. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #272 out of 682 companies in the Drug Manufacturers industry, placing it in the top 39.9%.
Is Laboratorios Farmaceuticos Rovi's EV-to-EBIT too high?
Laboratorios Farmaceuticos Rovi's current EV-to-EBIT of 12.42 is 46% below median its 10-year median of 23.18. Over the past 10 years, this metric has ranged from a low of 7.10 to a high of 102.09. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Laboratorios Farmaceuticos Rovi's value of 12.42 is 21.7% below this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #272 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #272 out of 682 companies for EV-to-EBIT. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median EV-to-EBIT is 15.86. Laboratorios Farmaceuticos Rovi's value of 12.42 is 21.7% below this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own EV-to-EBIT has ranged from 7.10 to 102.09 over the past decade. While the company's 10-year median is 23.18 vs. the industry median of 15.86, Laboratorios Farmaceuticos Rovi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current EV-to-EBIT of 12.42 is 21.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current EV-to-EBIT is 12.42, which is 46% below median its own 10-year median of 23.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (FRA:41L) is currently considered Fairly Valued. The stock's GF Value™ is €55.97, compared to a current price of €57.75 — trading 3.2% above its estimated fair value. The current EV-to-EBIT is 12.42, which is 46% below median its 10-year median of 23.18 and 21.7% below the Drug Manufacturers industry median of 15.86. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (FRA:41L), the current EV-to-EBIT is 12.42 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (FRA:41L) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €57.75 is trading 3.2% above its estimated GF Value™ of €55.97.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Fairly Valued.
Key valuation signals for FRA:41L:
EV-to-EBIT: 12.42 (46% below median its 10-year median of 23.18)
GF Value™: €55.97 vs. price of €57.75 (3.2% above fair value)
Industry Position: 21.7% below the Drug Manufacturers median (#272 of 682)
No single metric tells the full story. See the FRA:41L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score
Get the complete analysis for FRA:41L
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:41L has been successfully added to your 
